Universite de Montreal
54 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
0
Ending by 2030
Feb 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 18 to 25, 2026 · next Dec 18
- 4 fees due Jan 2 to 18, 2027 · next Jan 2
- 1 fee due Feb 15, 2027The maintenance fee for Selection of human hematopoetic stem cells using EPCR (US 11,725,187) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for Heterocyclic Mitochondrial Activity Inhibitors and Uses Thereof (US 11,760,754) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Jun 8, 2027The maintenance fee for Dynamic Shoulder Orthosis with Rehabilitating Adduction (US 9,204,989) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
- 1 fee due Jul 23, 2027The maintenance fee for Cyclic peptides and uses thereof (US 11,879,021) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
- 1 fee due Sep 10, 2027The maintenance fee for Renilla based biosensors for monitoring biomolecule localization and trafficking in cells (US 10,584,159) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells (US 10,647,718) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 1 US 12,721,812 Method for stimulating T cell response against lymphoblastic leukemia with leukemia tumor specific antigens
- 3 terms have ended since Aug 23, 2026
- Oct 14 US 8,860,943 High Sensitivity Plasmonic Structures for Use in Surface Plasmon Resonance Sensors and Method of Fabrication Thereof · lapsed on the fee record
- Sep 23 US 8,883,486 Arrestin biosensor · term ended
- Sep 18 US 10,077,236 Azacyclic Constrained Analogs of FTY720 · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,815,944 | Pharmaceutical composition with gelling properties containing a tyrosine derivative In force · USPTO record | In force | USPTO record | |
| US 9,029,097 | Biosensors for Monitoring Receptor-Mediated G-Protein Activation In force · High confidence | In force | High confidence | |
| US 9,018,395 | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators In force · USPTO record | In force | USPTO record | |
| US 10,342,817 | Combination therapy using ribavirin as elF4E inhibitor In force · USPTO record | In force | USPTO record | |
| US 9,409,906 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells In force · USPTO record | In force | USPTO record | |
| US 10,336,747 | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells In force · USPTO record | In force | USPTO record | |
| US 9,545,416 | Combination therapy using ribavirin as eIF4E inhibitor In force · USPTO record | In force | USPTO record | |
| US 9,204,989 | Dynamic Shoulder Orthosis with Rehabilitating Adduction In force · High confidence | In force | High confidence | |
| US 10,324,085 | Systems and methods for the monitoring of protein complex formation in cells In force · USPTO record | In force | USPTO record | |
| US 9,598,419 | Imidazotriazine and imidazodiazine compounds In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 39: 54 patents in force now held by others · 94 lapsed for an unpaid fee · 115 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 pending · 18 abandoned · 46 no status recorded